TCL Archive ACC Survey Preliminary Finding: Three Cancer DRG Categories “Clearly Underpaid Across The Board” January 25, 1985
TCL Archive Two Regorafenib Trials Demonstrate Efficacy, Improve Overall and Progression-Free Survival December 28, 2012
TCL Archive The Line Item for Cancer Centers and SPOREs to Remain Flat, Near $598 Million for the 2013 Fiscal Year April 20, 2012
TCL Archive Large, Conclusive Trials Provide Answers To Treatment Questions For GI Cancers June 26, 2009
